U.S.-China Heparin Scare Could Affect Indian Drug Makers
This article was originally published in PharmAsia News
Executive Summary
The scare surrounding tainted Chinese heparin could have an impact on Indian drug makers. The discovery that the active ingredient in blood-clotting drugs was tainted by Chinese suppliers has increased quality concerns by U.S. firms that obtain ingredients from China and India. Indian firms may be tempted to dismiss the concern as a problem China must deal with, but India often is mentioned as part of a general problem with sources of ingredients. One U.S. drug consultant says many companies are looking to Indian sources to replace Chinese sources, likely adding to U.S. scrutiny. (Click here for more